

- Biermann JS, Adkins DR, Agulnik M, et al. Bone cancer. *J Natl Compr Cancer Netw* 2013;11:688–723.
- Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. *CA Cancer J Clin* 2014;64:9–29.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
- Ottaviani G, Jaffe N. The etiology of osteosarcoma. *Cancer Treat Res* 2009;152:15–32.
- Lessnick SL, Ladanyi M. Molecular pathogenesis of Ewing sarcoma: New therapeutic and transcriptional targets. *Annu Rev Pathol* 2012;7:145–159.
- Szuhai K, Cleton-Jansen AM, Hogendoorn PC, et al. Molecular pathology and its diagnostic use in bone tumors. *Cancer Genet* 2012;205:193–204.
- Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome? *Ann Intern Med* 1969;71:747–752.
- Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 1990;250:1233–1238.
- McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. *J Clin Oncol* 1994;12:925–930.
- Ognjanovic S, Olivieri M, Bergemann TL, et al. Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database. *Cancer* 2012;118:1387–1396.
- Mai PL, Malkin D, Garber JE, et al. Li-Fraumeni syndrome: Report of a clinical research workshop and creation of a research consortium. *Cancer Genet* 2012;205:479–487.
- Hansen MF, Koufos A, Gallie BL, et al. Osteosarcoma and retinoblastoma: A shared chromosomal mechanism revealing recessive predisposition. *Proc Natl Acad Sci U S A* 1985;82:6216–6260.
- Toguchida J, Ishizaki K, Sasaki MS, et al. Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. *Cancer Res* 1988;48:3939–3943.
- Cance WG, Brennan MF, Dudas ME, et al. Altered expression of the retinoblastoma gene product in human sarcomas. *N Engl J Med* 1990;323:1457–1462.
- Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. *Br J Cancer* 1986;53:661–671.
- Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. *Nature* 1992;359:162–165.
- Sorenson PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. *Nat Genet* 1994;6:146–151.
- Erkizan H, Uversky VN, Toretsky JA. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. *Clin Cancer Res* 2010;16:4077–4083.
- Kelleher FC, Cain JE, Healy JM, et al. Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. *Pharmacol Ther* 2012;136:153–168.
- Bovéé JV, Hogendoorn PC, Wunder JS, et al. Cartilage tumours and bone development: Molecular pathology and possible therapeutic targets. *Nat Rev Cancer* 2010;10:481–488.
- Kalra S, Grimer RJ, Spooner D, et al. Radiation-induced sarcomas of bone: Factors that affect outcome. *J Bone Joint Surg Br* 2007;89-B:808–813.
- Samartzis D, Nishi N, Hayashi M, et al. Exposure to ionizing radiation and development of bone sarcoma: New insights based on atomic-bomb survivors of Hiroshima and Nagasaki. *J Bone Joint Surg Br* 2011;93-A:1008–1015.
- Le Vu B, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. *Int J Cancer* 1998;77:370–377.
- Shaylor PJ, Peake D, Grimer RJ, et al. Paget's osteosarcoma—No cure in sight. *Sarcoma* 1999;3:191–192.
- Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. *J Bone Miner Res* 2006;21:P58–P63.
- Mangham DC, Davie MW, Grimer RJ. Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation. *Bone* 2009;44:431–436.
- Witkin GB, Guilford WB, Siegal GP. Osteogenic sarcoma and soft tissue myxoma in a patient with fibrous dysplasia and hemoglobins J Baltimore and S. *Clin Orthop Relat Res* 1986;204:245–252.
- Ruggieri P, Sim FH, Bond JR, et al. Osteosarcoma in a patient with polyostotic fibrous dysplasia and Albright's syndrome. *Orthopedics* 1995;18:71–75.
- Jhala DN, Eltoum I, Carroll AJ, et al. Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud's syndrome: a case report emphasizing the cytological and cytogenetic findings. *Hum Pathol* 2003;34:1354–1357.
- Sadeghi SM, Hosseini SN. Spontaneous conversion of fibrous dysplasia into osteosarcoma. *J Craniofac Surg* 2011;22:959–961.
- Van Rossem C, Pauwels P, Somville J, et al. Sarcomatous degeneration in fibrous dysplasia of the rib cage. *Ann Thorac Surg* 2013;96:e89–e90.
- Ahmed AR, Tan TS, Unni KK, et al. Secondary chondrosarcoma in osteochondroma: Report of 107 patients. *Clin Orthop Relat Res* 2003;411:193–206.
- Schmale GA, Conrad EU III, Raskind WH. The natural history of hereditary multiple exostoses. *J Bone Joint Surg Am* 1994;76-A:986–992.
- Lin PP, Moussallem CD, Deavers MT. Secondary chondrosarcoma. *J Am Acad Orthop Surg* 2010;18:608–615.
- Horvai A, Unni KK. Premalignant conditions of bone. *J Orthop Sci* 2006;11:412–423.
- Puri A, Parasnis AS, Udupa KV, et al. Fibroblastic osteosarcoma arising in chronic osteomyelitis. *Clin Radiol* 2003;58:170–172.
- Druschel C, Pirvu T, Schasser KD, et al. Osteosarkommanifestation bei chronischer Osteomyelitis. *Der Unfallchirurg* 2013;116:854–859.
- Domson GF, Shahlee A, Reith JD, et al. Infarct-associated bone sarcomas. *Clin Orthop Relat Res* 2009;467:1820–1825.
- Wold LE, Unni KK, Sim FH, et al. *Atlas of Orthopedic Pathology*. Philadelphia: Saunders; 2008:179.
- Ayoub KS, Grimer RJ, Carter SR, et al. Clear cell chondrosarcoma of bone. *Sarcoma* 1999;3:115–119.
- Lewis VO, Gebhardt MC, Springfield DS. Parosteal osteosarcoma of the posterior aspect of the distal part of the femur. *J Bone Joint Surg Am* 2000;82-A:1083–1088.
- Cesari M, Alberghini M, Vanel D, et al. Periosteal osteosarcoma: a single-institution experience. *Cancer* 2011;117:1731–1735.
- Most MJ, Sim FH, Inwards CY. Osteofibrous dysplasia and adamantinoma. *J Am Acad Orthop Surg* 2010;18:358–366.
- Schwab JH, Springfield DS, Raskin KA, et al. What's new in primary malignant musculoskeletal tumors. *J Bone Joint Surg Am* 2013;95-A:2240–2246.
- Choi LE, Helaey JH, Kuk D, et al. Analysis of outcomes in extraskeletal osteosarcoma: a review of fifty-three cases. *J Bone Joint Surg Am* 2014;96-A:e2.
- Orr WS, Denbo JW, Billups CA, et al. Analysis of prognostic factors in extraskeletal Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. *Ann Surg Oncol* 2012;19:3816–3822.
- Ogura K, Fujiwara T, Beppu Y, et al. Extraskeletal myxoid chondrosarcoma: a review of 23 patients treated at a single referral center with long-term follow-up. *Arch Orthop Trauma Surg* 2012;132:1379–1386.
- Fletcher CDM, Bridge JA, Hogendoorn PC, et al. *WHO Classification of Tumours of Soft Tissue and Bone*. 4th ed. Lyon: IARC; 2013.
- Bertoni F, Unni KK, Beabout JW, et al. Chondrosarcoma of the synovium. *Cancer* 1991;67:155–162.
- Enneking WF, Dunham W, Gebhardt M, et al. A system for the classification of skeletal resections. *Chir Organi Mov* 1990;75:217–240.
- Enneking WF, Dunham W, Gebhardt MC, et al. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. *Clin Orthop Relat Res* 1993;286:241–246.
- Podoloff DA, Advani RH, Allred C, et al. NCCN Task Force Report: PET/CT scanning in cancer. *J Natl Compr Cancer Netw* 2007;5:S1–S22.
- Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. *Eur J Nucl Med* 2002;29:1149–1154.
- Hawkins DS, Rajendran JG, Conrad EU III, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-Fluorodeoxy-D-Glucose positron emission tomography. *Cancer* 2002;94:3277–3284.
- Bredella MA, Caputo GR, Steinbach LS. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. *AJR Am J Roentgenol* 2002;179:1145–1150.
- Hawkins DS, Conrad EU III, Butrynski JE, et al. [F-18]-fluorodeoxy-D-glucose positron emission tomography is associated with outcome for extremity osteosarcoma in children and young adults. *Cancer* 2009;115:3519–3525.
- Eary JF, Conrad EU, O'Sullivan J, et al. Sarcoma mid-therapy [F-18] fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome. *J Bone Joint Surg Am* 2014;96-A:152–158.
- Treglia G, Salsano M, Stefanelli A, et al. Diagnostic accuracy of 18F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis. *Skeletal Radiol* 2012;41:249–256.
- Snyder BD, Hauser-Kara DA, Hipp JA, et al. Predicting fracture through benign skeletal lesions with quantitative computed tomography. *J Bone Joint Surg Am* 2006;88-A:55–70.
- Skrzynski MC, Biermann JS, Montag A, et al. Diagnostic accuracy and charge-savings of outpatient core needle biopsy compared with open biopsy of musculoskeletal tumors. *J Bone Joint Surg Am* 1996;78-A:644–649.
- van der Bijl AE, Taminiu AH, Hermans J, et al. Accuracy of the Jamshidi trocar biopsy in the diagnosis of bone tumors. *Clin Orthop Relat Res* 1997;334:233–243.
- Dupuy DE, Rosenberg AE, Punyatabandhu T, et al. Accuracy of CT-guided needle biopsy of musculoskeletal neoplasms. *Am J Radiol* 1998;171:759–762.
- Saifuddin A, Mitchell R, Burnett SJD, et al. Ultrasound-guided needle biopsy of primary bone tumors. *J Bone Joint Surg Am* 2000;82-B:50–54.
- Wedin R, Bauer HC, Skoog L, et al. Cytological diagnosis of skeletal lesions: Fine-needle aspiration biopsy in 110 tumours. *J Bone Joint Surg Am* 2000;82-B:673–678.
- Carrino JA, Khurana B, Ready JE, et al. Magnetic resonance imaging-guided percutaneous biopsy of musculoskeletal lesions. *J Bone Joint Surg Am* 2007;89-A:2179–2187.

66. Virayavanich W, Ringler MD, Chin CT, et al. CT-guided biopsy of bone and soft-tissue lesions: role of on-site immediate cytologic evaluation. *J Vasc Interv Radiol* 2011;22:1024–1030.
67. UyBico SJ, Motamedi K, Omura MC, et al. Relevance of compartmental anatomic guidelines for biopsy of musculoskeletal tumors: retrospective review of 363 biopsies over a 6-year period. *J Vasc Interv Radiol* 2012;23:511–518.
68. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft tissue tumors. *J Bone Joint Surg Am* 1982;64-A:1121–1127.
69. Mankin HJ, Mankin CJ, Simon MA. The hazards of biopsy, revisited. *J Bone Joint Surg Am* 1996;78-A:656–663.
70. Athanasian EA. Biopsy of musculoskeletal tumors. In: Menendez LR, ed. *Orthopaedic Knowledge Update: Musculoskeletal Tumors*. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2002:29–33.
71. Ashford RU, McCarthy SW, Scolyer RA, et al. Surgical biopsy with intraoperative frozen section. An accurate and cost-effective method for diagnosis of musculoskeletal sarcomas. *J Bone Joint Surg Am* 2006;88-B:1207–1211.
72. Edge SB, Byrd DR, Compton CC, et al. *AJCC Cancer Staging Manual*, 7th ed. Philadelphia: Lippincott Raven; 2009.
73. Bacci G, Picci P, Citelis S, et al. The treatment of localized Ewing's sarcoma: the experience at the Istituto Rizzoli in 163 cases treated with and without adjuvant chemotherapy. *Cancer* 1982;49:1561–1570.
74. Chan RC, Sutow WW, Lindberg RD, et al. Management and results of localized Ewing's sarcoma. *Cancer* 1979;43:1001–1006.
75. Zucker JM, Henry-Amar M, Sarrazin D, et al. Intensive systemic chemotherapy in localized Ewing's sarcoma. A historical trial. *Cancer* 1983;52:415–423.
76. Rosen G, Caparros B, Mosenel C, et al. Curability of Ewing's sarcoma and considerations for future therapeutic trials. *Cancer* 1978;41:888–899.
77. Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. *J Clin Oncol* 1990;8:1664–1674.
78. Jürgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. *Cancer* 1988;61:23–32.
79. Craft AW, Cotterill SJ, Bullimore JA, et al. Long-term results from the first UKCCSG Ewing's tumour study (ET-1). *Eur J Cancer* 1997;33:1061–1069.
80. Oberlin O, Patte C, Demeocq F, et al. The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. *Eur J Cancer Clin Oncol* 1985;21:463–467.
81. Oberlin O, Le Deley MC, Bui BN, et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). *Br J Cancer* 2001;85:1646–1654.
82. Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IE88-II. *J Clin Oncol* 1990;8:1514–1524.
83. Oberlin O, Habrand JL, Zucker JM, et al. No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. *J Clin Oncol* 1992;10:1407–1412.
84. Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. *J Clin Oncol* 1998;16:3628–3633.
85. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CE88 86. *J Clin Oncol* 2001;19:1818–1829.
86. Rosito P, Mancini AF, Rondelli R, et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: A preliminary report of 6 years of experience. *Cancer* 1999;86:421–428.
87. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. *N Engl J Med* 2003;348:694–701.
88. Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—a Children's Cancer Group and Pediatric Oncology Group study. *J Clin Oncol* 2004;22:2873–2876.
89. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group study. *J Clin Oncol* 2009;27:2536–2541.
90. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. *J Clin Oncol* 2012;30:4148–4154.
91. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 study: two randomized trials of Ewing's sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. *J Clin Oncol* 2008;26:4385–4393.
92. Hayes FA, Thompson EI, Kumar M, et al. Long-term survival in patients with Ewing's sarcoma relapsing after completing treatment. *Med Pediatr Oncol* 1987;15:254–256.
93. Ferrari S, Brach del Prever A, Palmerini E, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. *Pediatr Blood Cancer* 2009;52:581–584.
94. Navid F, Reikes Willert J, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. *Cancer* 2008;113:419–425.
95. Rapkin L, Qayed M, Brill P, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. *Pediatr Blood Cancer* 2012;59:854–858.
96. Fox E, Patel S, Wathen JK, et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of the Sarcoma Alliance for Research Through Collaboration study 003. *Oncologist* 2012;17:e321–e329.
97. Mora J, Cruz CO, Parareda A, et al. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. *J Pediatr Hematol Oncol* 2009;31:723–729.
98. Lee EM, Rha SY, Lee J, et al. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. *Cancer Chemother Pharmacol* 2012;69:635–642.
99. Saylor RL III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group Phase II Study. *J Clin Oncol* 2001;19:3463–3469.
100. Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. *Pediatr Blood Cancer* 2006;47:795–800.
101. Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group phase II study 9457—A report from the Children's Oncology Group. *J Clin Oncol* 2006;24:152–159.
102. Wagner LM, Crews KR, Jacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. *Clin Cancer Res* 2004;10:840–848.
103. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. *Pediatr Blood Cancer* 2007;48:132–139.
104. Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. *Pediatr Blood Cancer* 2009;53:1029–1034.
105. Raciborska A, Bilka K, Drabko K, et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. *Pediatr Blood Cancer* 2013;60:1621–1625.
106. Barker LM, Pendergrass TW, Sanders JE, et al. Survival after recurrence of Ewing's sarcoma family of tumors. *J Clin Oncol* 2005;23:4354–4362.
107. Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. *J Clin Oncol* 2001;19:2812–2820.
108. Luksch R, Tienghi A, Hall KS, et al. Primary metastatic Ewing's family of tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV study including myeloablative chemotherapy and total lung-irradiation. *Ann Oncol* 2012;23:2970–2976.
109. Oberlin O, Rey A, Desfachelles AS, et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société des Cancéris de l'Enfant. *J Clin Oncol* 2006;24:3997–4002.
110. Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. *J Clin Oncol* 2010;28:3284–3291.
111. Ferrari S, Sundby Hall K, Luksch R, et al. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Group III protocol. *Ann Oncol* 2011;22:1221–1227.
112. Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. *Pediatr Blood Cancer* 2006;47:22–29.
113. Stegmaier K, Wong JS, Ross KN, et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI1 modulator in Ewing sarcoma. *PLoS Med* 2007;4:e122.
114. DuBois SG, Krailo MD, Lessnick SL, et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2009;52:324–327.
115. Erkizan H, Kong Y, Merchant M, et al. Small molecule selected to disrupt oncogenic protein EWS-FLI1 interaction with RNA Helicase A inhibits Ewing's sarcoma. *Nat Med* 2009;15:750–756.
116. Grohar PJ, Woldemichael GM, Griffin LB, et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. *J Natl Cancer Inst* 2011;103:962–978.
117. DuBois SG, Marina N, Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. *Cancer* 2010;116:749–757.
118. Felgenhauer JL, Nieder ML, Krailo MD, et al. A pilot study of low-dose anti-angiogenesis chemotherapy in combination with standard multiagent chemotherapy for patients with newly-diagnosed metastatic Ewing sarcoma family of tumors: a Children's Oncology Group (COG) phase II study NCT00061893. *Pediatr Blood Cancer* 2013;60:409–414.

119. Wagner L, Turpin B, Nagarajan R, et al. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. *Pediatr Blood Cancer* 2013;60:1447–1451.
120. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. *J Clin Invest* 1990;86:1806–1814.
121. Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. *Mol Cell Biol* 2004;24:7275–7283.
122. Houghton PJ, Morton CL, Gorlick R, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2010;54:921–926.
123. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor of Ewing's sarcoma. *Clin Cancer Res* 2007;13:1322–1330.
124. Martins AS, Mackintosh C, Herrero Martín D, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. *Clin Cancer Res* 2006;12:3532–3540.
125. Scottandi K, Benini S, Nanni P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. *Cancer Res* 1998;58:4127–4131.
126. Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. *J Clin Oncol* 2012;30:256–262.
127. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 749, a fully human monoclonal antibody to insulin-like growth factor receptor 1. *J Clin Oncol* 2009;27:5800–5807.
128. Juergens H, Daw NC, Georger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type I receptor antibody figitumumab in patients with refractory Ewing sarcoma. *J Clin Oncol* 2011;29:4534–4540.
129. Pappo AS, Patel SR, Crowley J, et al. RI507, a monoclonal antibody to the insulin-like growth factor I receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research Through Collaboration study. *J Clin Oncol* 2011;29:4541–4547.
130. Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. *J Clin Oncol* 2012;30:1849–1856.
131. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. *Oncogene* 2003;22:9282–9287.
132. Houghton PJ, Morton CL, Gorlick R, et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. *Mol Cancer Ther* 2010;9:101–112.
133. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. *Pediatr Blood Cancer* 2008;50:799–805.
134. Mita M, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. *J Clin Oncol* 2008;26:361–367.
135. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. *Nature* 2012;483:570–577.
136. Brenner JC, Feng FY, Han S, et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. *Cancer Res* 2012;72:1608–1613.
137. Carrie C, Mascard E, Gomez F, et al. Nonmetastatic pelvic Ewing sarcoma: report of the French Society of Pediatric Oncology. *Med Pediatr Oncol* 1999;33:444–449.
138. Wilkins RM, Pritchard DJ, Burgert EO Jr, et al. Ewing's sarcoma of bone. Experience with 140 patients. *Cancer* 1986;58:2551–2555.
139. Yock TI, Krailo M, Fryer CJ, et al. Local control in pelvic Ewing sarcoma: analysis from INT-0091—a report from the Children's Oncology Group. *J Clin Oncol* 2006;24:3838–3843.
140. Dunst J, Schuck A. Role of radiotherapy in Ewing tumors. *Pediatr Blood Cancer* 2004;42:465–470.
141. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. *Lancet* 2002;359:2235–2241.
142. Seddon BM, Cassoni AM, Galloway MJ, et al. Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. *Clin Oncol* 2005;17:385–390.
143. Carrie C, Le Deley MC, Claude L. The radiosensitization effect and toxicity of busulfan containing chemotherapy before radiotherapy for Ewing's sarcoma. *Strahlentherapie Und Onkologie* 2009;185:31.
144. Bölling T, Dirksen U, Ranft A, et al. Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data. *Strahlentherapie Und Onkologie* 2009;185:21–22.
145. Lo SS, Sahgal A, Wang JZ, et al. Stereotactic body radiation therapy for spinal metastases. *Discov Med* 2010;9:289–296.
146. Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation therapy: a novel treatment modality. *Nat Rev Clin Oncol* 2010;7:44–54.
147. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. *N Engl J Med* 1986;314:1600–1606.
148. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. *J Clin Oncol* 2003;21:1574–1580.
149. Bacci G, Gherlizoni F, Picci P, et al. Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. *Eur J Cancer Clin Oncol* 1986;22:1337–1345.
150. Krailo MD, Ertel I, Makley J, et al. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Children's Cancer Study Group. *Med Pediatr Oncol* 1987;15:69–77.
151. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. *J Clin Oncol* 1984;2:617–624.
152. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histologic tumor response. *J Clin Oncol* 1988;6:329–337.
153. Bramwell V, Rouses J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma—reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* 1994;12:1137–1149.
154. Souhami RL, Craft AW, Van der Eijken J, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. *Lancet* 1997;350:911–917.
155. Lewis JJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. *J Natl Cancer Inst* 2007;99:112–128.
156. Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. *J Clin Oncol* 1998;16:3641–3648.
157. Ferrari S, Ruggieri P, Cefalo G, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian Sarcoma Group Trial ISG/OS-1. *J Clin Oncol* 2012;30:2112–2118.
158. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. *J Clin Oncol* 2005;23:2004–2011.
159. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children's Oncology Group. *J Clin Oncol* 2008;26:633–638.
160. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a Pediatric Oncology Group Trial. *J Clin Oncol* 2002;20:426–433.
161. Le Deley MC, Guinebretière JM, Gentet JC, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. *Eur J Cancer* 2007;43:752–761.
162. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. *J Clin Oncol* 1987;5:1191–1198.
163. Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. *Eur J Cancer* 1997;33:232–237.
164. Lee HY, Shin SJ, Kim HS, et al. Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. *Cancer Treat Res* 2012;44:43–49.
165. Ebb D, Meyers P, Grier H, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children's Oncology Group. *J Clin Oncol* 2012;30:2545–2551.
166. Heiner JP, Miraldi F, Kallick S, et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. *Cancer Res* 1987;47:5377–5381.
167. Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. *J Clin Oncol* 1994;12:184–193.
168. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. *J Clin Oncol* 1998;16:2169–2180.
169. Kleinerman ES, Gano JB, Johnston DA, et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. *Am J Clin Oncol* 1995;18:93–99.
170. Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. *Cancer* 2009;115:5339–5348.



171. Müller CR, Smeland S, Bauer HC, et al. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. *Acta Oncol* 2005;44:475-480.
172. Bielack SS, Smeland S, Whelan J, et al. MAP plus maintenance pegylated interferon alpha-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 "good response" randomization. *J Clin Oncol* 2013;31:LBA10504.
173. Heymann D, Ory B, Gouin F, et al. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. *Trends Mol Med* 2004;10:337-343.
174. Meyers PA, Helacy JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. *Cancer* 2011;117:1736-1744.
175. Goldsby RE, Fan TM, Villaluna D, et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report of the Children's Oncology Group. *Eur J Cancer* 2013;49:2384-2391.
176. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. *Ann Oncol* 2012;23:508-516.
177. Arndt CA, Koshkina NV, Inwards CY, et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. A report from the Children's Oncology Group. *Clin Cancer Res* 2010;16:4024-4030.
178. Chou AJ, Gupta R, Bell MD, et al. Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. *Pediatr Blood Cancer* 2013;60:580-586.
179. Ogawa Y, Takahashi T, Kobayashi T, et al. Mechanism of apoptotic resistance of human osteosarcoma cell line, HS-Os-1, against irradiation. *Int J Mol Med* 2003;12:453-458.
180. Ozaki T, Flege S, Liljenqvist U, et al. Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. *Cancer* 2002;94:1069-1077.
181. Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. *J Clin Oncol* 2003;21:334-341.
182. Machak GN, Tkachev SI, Solovyev YN, et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. *Mayo Clin Proc* 2003;78:147-155.
183. Kamada T, Imai R, Serizawa I. Carbon ion radiotherapy in bone and soft tissue sarcoma. Presented at the Proceedings of NRS-MD Anderson Symposium on Clinical Issues for Particle Therapy, 2008.
184. Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. *Cancer* 2011;117:4522-4530.
185. Longhi A, Errani C, Gonzales-Arabbio D, et al. Osteosarcoma in patients older than 65 years. *J Clin Oncol* 2008;26:5368-5373.
186. Ganjoo KN, Patel S. The treatment outcome for adult patients with Ewing's sarcoma. *Curr Oncol Rep* 2013;15:372-377.
187. Levy JC, Temple HT, Mollabashy A, et al. The causes of pain in benign solitary enchondromas of the proximal humerus. *Clin Orthop Relat Res* 2005;431:181-186.
188. Eefting D, Schrage YM, Gerinaerd MJ, et al. Assessment of intraobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. *Am J Surg Pathol* 2009;33:50-57.
189. Grimer RJ, Bielack S, Flege S, et al. Periosteal osteosarcoma—a European review of outcome. *Eur J Cancer* 2005;41:2806-2811.
190. Rose PS, Dickey ID, Wenger DE, et al. Periosteal osteosarcoma: long-term outcome and risk of late recurrence. *Clin Orthop Relat Res* 2006;453:314-317.
191. Weddington WW Jr, Segraves KB, Simon MA. Psychological outcome of extremity sarcoma survivors undergoing amputation or limb salvage. *J Clin Oncol* 1985;3:1393-1399.
192. Simon MA, Aschliman MA, Thomas N, et al. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. *J Bone Joint Surg Am* 1986;68-A:1331-1337.
193. Harris IE, Leff AR, Gitelis S, et al. Function after amputation, arthrodesis, or arthroplasty for tumors about the knee. *J Bone Joint Surg Am* 1990;72-A:1477-1485.
194. Rougraff BT, Simon MA, Kniesl JS, et al. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. *J Bone Joint Surg Am* 1994;76-A:649-656.
195. Davis AM, Devlin M, Griffin AM, et al. Functional outcome in amputation versus limb sparing of patients with lower extremity sarcoma: a matched case-control study. *Arch Phys Med Rehabil* 1999;80:615-618.
196. Refaat Y, Gunnoe J, Hornicek FJ, et al. Comparison of quality of life after amputation or limb salvage. *Clin Orthop Relat Res* 2002;397:298-305.
197. Kong CB, Song WS, Cho WH, et al. Local recurrence has only a small effect of survival in high-risk extremity osteosarcoma. *Clin Orthop Relat Res* 2012;470:1482-1490.
198. Grimer RJ, Carter SR, Pynsent PB. The cost effectiveness of limb salvage for bone tumours. *J Bone Joint Surg Br* 1997;79-B:558-561.
199. O'Donnell RJ, Burch S. Hemipelvectomy and hemicorporectomy: Hind-quarter amputation. In: Ames CP, Boriani S, Jandial R, eds. *Spine and Spinal Cord Tumors*. St. Louis, MO: AMP/CRC Press; 2013:759-766.
200. Burgess EM, Romano RL. The management of lower extremity amputees using immediate postsurgical prostheses. *Clin Orthop Relat Res* 1968;57:137-146.
201. Burgess EM. Immediate postsurgical fitting: a system of amputee management. *Phys Ther* 1971;51:139-143.
202. Folsom D, King T, Rubin JR. Lower-extremity amputation with immediate postoperative prosthetic placement. *Am J Surg* 1992;164:320-322.
203. Harrington JJ, Lexier R, Woods JM, et al. A plaster-pylon technique for below-knee amputation. *J Bone Joint Surg Br* 1991;73-B:76-78.
204. Nyström LM, Morcuende JA. Expanding endoprosthesis for pediatric musculoskeletal malignancy: current concepts and results. *Iowa Orthop J* 2010;30:141-149.
205. Henderson ER, Pepper AM, Marulanda G, et al. Outcome of lower-limb preservation with an expandable endoprosthesis after bone tumor resection in children. *J Bone Joint Surg Am* 2012;94-A:537-547.
206. Hillman A, Hoffman C, Gosheger G, et al. Malignant tumor of the distal part of the femur or the proximal part of the tibia: endoprosthetic replacement or rotationplasty. Functional outcome and quality-of-life measurements. *J Bone Joint Surg Am* 1999;81-A:462-467.
207. Cammisia FP, Glasser DB, Otis JC, et al. The Van Nes tibial rotationplasty. A functionally viable reconstructive procedure in children who have a tumor of the distal end of the femur. *J Bone Joint Surg Am* 1990;72-A:1541-1547.
208. Gupta SK, Allassaf N, Harrop AR, et al. Principles of rotationplasty. *J Am Acad Orthop Surg* 2012;20:657-667.
209. Van Nes CP. Transplantation of the tibia and fibula to replace the femur following resection: "Turn-up-plasty" of the leg. *J Bone Joint Surg Am* 1948;30-A:854-858.
210. McDonald DJ, Scott SM, Eckardt JJ. Tibial turn-up for long distal femoral bone loss. *Clin Orthop Relat Res* 2001;383:214-220.
211. Brånemark P-I. *The Osseointegration Book: From Calvarium to Calcaneus*. Berlin: Quintessenz Verlags-GmbH; 2005.
212. Aschoff HH, Kennon RE, Keggi JM, et al. Transcutaneous, distal femoral, intramedullary attachment for above-the-knee prostheses: an endo-exo device. *J Bone Joint Surg Am* 2010;92-A:180-186.
213. Hagberg K, Brånemark R. One hundred patients treated with osseointegrated transfemoral amputation prostheses—rehabilitation perspective. *J Rehabil Res Dev* 2009;46:331-344.
214. Brånemark R, Berlin Ö, Hagberg K, et al. A novel osseointegrated percutaneous prosthetic system for the treatment of patients with transfemoral amputation: a prospective study of 51 patients. *J Bone Joint Surg Br* 2014;96-B:106-113.
215. Capanna R, Campanacci DA, Belot N, et al. A new reconstructive technique for intercalary defects of massive allograft with vascularized fibular autograft. Long-term results and comparison with alternative techniques. *Orthop Clin North Am* 2007;38:51-60.
216. Chert M, Colterjohn N, Manfrini M. The use of vascularized fibular grafts in skeletal reconstruction for bone tumors in children. *J Am Acad Orthop Surg* 2007;15:577-587.
217. Tomford WW. Transmission of disease through transplantation of musculoskeletal allografts. *J Bone Joint Surg Am* 1995;77-A:1742-1754.
218. Fox EJ, Hau MA, Gebhardt MC, et al. Long-term followup of proximal femoral allografts. *Clin Orthop Relat Res* 2002;397:106-113.
219. Ogilvie CM, Crawford EA, Hosalkar HS, et al. Long-term results for limb salvage with osteoarticular allograft reconstruction. *Clin Orthop Relat Res* 2009;467:2685-2690.
220. Hejna MJ, Gitelis S. Allograft prosthetic composite replacement for bone tumors. *Semin Surg Oncol* 1997;13:18-24.
221. Henderson ER, Groundland JS, Pala E, et al. Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review. *J Bone Joint Surg Am* 2011;93-A:418-429.
222. Cristofolini L, Bini SA, Toni A. In vitro testing of a novel limb salvage prosthesis for the distal femur. *Clin Biomech (Bristol, Avon)* 1998;13:608-615.
223. Bini SA, Johnston JO, Martin DL. Compliant prestress fixation in tumor prostheses: interface retrieval data. *Orthopedics* 2000;23:707-712.
224. Avedian RS, Goldsby RE, Kramer MJ, et al. Effect of chemotherapy on initial compressive osseointegration of tumor endoprostheses. *Clin Orthop Relat Res* 2007;459:48-53.
225. O'Donnell RJ. Compressive osseointegration of modular endoprostheses. *Curr Opin Orthop* 2007;18:590-603.
226. Kramer MJ, Tanner BJ, Horvai AE, et al. Compressive osseointegration promotes viable bone at the endoprosthetic interface: retrieval study of Compress® implants. *Int Orthop* 2008;32:567-571.
227. Tyler WK, Healey JH, Morris CD, et al. Compress® periprosthetic fractures. *Clin Orthop Relat Res* 2009;467:2800-2806.
228. Davis JM, Robins RJ, Frink SJ, et al. Use of a compression tumor implant with total elbow arthroplasty for traumatic distal humeral bone loss in a young woman. *J Shoulder Elbow Surg* 2010;19:e24-e28.
229. Abrams GD, Gajendran VK, Mohler DG, et al. Surgical technique: Methods for removing a Compress® compliant prestress implant. *Clin Orthop Relat Res* 2012;470:1204-1212.
230. Schwartz AJ, Beauchamp CP. Compressive osseointegration into a custom acetabular implant masquerading as tumor recurrence: A case report. *Clin Orthop Relat Res* 2013;471:878-882.
231. Bhangu AA, Kramer MJ, Grimer RJ, et al. Early distal femoral endoprosthetic survival: cemented stems versus the Compress® implant. *Int Orthop* 2006;30:465-472.

232. O'Donnell RJ. Compressive osseointegration of tibial implants in primary cancer reconstruction. *Clin Orthop Relat Res* 2009;467:2807–2812.
233. Farfalli GL, Boland PJ, Morris CD, et al. Early equivalence of uncemented press-fit and femoral Compress® femoral fixation. *Clin Orthop Relat Res* 2009;467:2792–2799.
234. Pedtke AC, Wustrack RL, Fang AS, et al. Aseptic failure: how does the Compress® implant compare to cemented stems? *Clin Orthop Relat Res* 2011;470:735–742.
235. Healey JH, Morris CD, Athanasian EA, et al. Compress® knee arthroplasty has 80% 10-year survivorship and novel forms of bone failure. *Clin Orthop Relat Res* 2013;471:774–783.
236. Calvert GT, Cummings JE, Bowles AJ, et al. A dual-center review of compressive osseointegration for fixation of massive endoprosthesis: 2- to 9-year followup. *Clin Orthop Relat Res* 2013;472:822–829.
237. Weisstein JS, Goldsby RE, O'Donnell RJ. Oncologic approaches to pediatric limb preservation. *J Am Acad Orthop Surg* 2005;13:544–554.
238. Miller BJ, Lynch CF, Buckwalter JA. Conditional survival is greater than overall survival at diagnosis in patients with osteosarcoma and Ewing's sarcoma. *Clin Orthop Relat Res* 2013;471:3398–3404.
239. Garner HW, Kransdorf MJ, Peterson JJ. Posttherapy imaging of musculoskeletal neoplasms. *Radiol Clin North Am* 2011;49:1307–1323.
240. Merimsky O, Kollender Y, Inbar M, et al. Palliative treatment for advanced or metastatic osteosarcoma. *Isr Med Assoc J* 2004;6:34–38.
241. Errani C, Longhi A, Rossi C, et al. Palliative therapy for osteosarcoma. *Expert Rev Anticancer Ther* 2011;11:217–227.
242. Levy MH, Adolph MD, Back A, et al. Palliative care. *J Natl Compr Cancer Netw* 2012;10:1284–1309.